Brief: Qurient Announces U.S. FDA Clearance Of Ind Application For Q901, A Novel Cancer Therapy
08/02/2022 15:05
Qurient Co Ltd 115180.KQ :
* QURIENT ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION
FOR
Q901, A NOVEL CANCER THERAPY
* QURIENT CO LTD - PHASE 1/2 CLINICAL STUDY IN PATIENTS WITH
ADVANCED SOLID TUMOR EXPECTED TO START IN 2Q2022
Source text for Eikon: ID:nBw5JlV0fa
Further company coverage: 115180.KQ
Recent news on Qurient
See all newsBrief: Lonza Expands Dual-Payload ADC Technology Offering Through Access To Qurient's CDK7 Inhibitors
Brief: Qurient To Conduct Capital Increase Of 8 Billion Won For Operational Funds
Brief: Qurient Therapeutics Enters Crada With The National Cancer Institute To Collaborate On A Phase 1/2 Clinical Study Of Q901 In Combination With Trop2-Adc
Brief: Qurient Announces Dosing Of First Patient In Q901 Phase 1/2 Clinical Study For The Treatment Of Patients With Solid Tumors
Brief: Qurient Announces Collaboration Agreement With MSD